Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation

por Barberio, Brigida, Savarino, Edoardo Vincenzo, Card, Timothy, Canova, Cristina, Baldisser, Francesco, Gubbiotti, Alessandro, Massimi, Davide, Ghisa, Matteo, Zingone, Fabiana
Publicado 2022

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study

por Barberio, Brigida, Zingone, Fabiana, D'Incà, Renata, Rovigo, Laura, Bertani, Lorenzo, Bodini, Giorgia, Ghisa, Matteo, Gubbiotti, Alessandro, Massimi, Davide, Lorenzon, Greta, Savarino, Edoardo Vincenzo
Publicado 2020

Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study

por Marinelli, Carla, Zingone, Fabiana, Lupo, Maria Giovanna, Marin, Raffaella, D’Incà, Renata, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, Barberio, Brigida, Ferri, Nicola, Savarino, Edoardo
Publicado 2022

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

por Cingolani, Linda, Barberio, Brigida, Zingone, Fabiana, Ferronato, Antonio, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Melatti, Piera, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, D’Incà, Renata, Savarino, Edoardo Vincenzo
Publicado 2021